‘ s
K 03306 DEC IN, 200°
a
510(k) Summary
6. 192
ArthroCare Corporation a
ArthroCare ArthroWands
General Information
Submitter Name/Address: ArthroCare Corporation
680 Vaqueros Avenue
Sunnyvale, CA 94085-3523
Establishment Registration Number: 2951580
Contact Person: Valerie Defiesta-Ng
Director, Regulatory Affairs
Date Prepared: November 6, 2008
Device Description
Trade Name: ArthroCare ArthroWands®
Generic/Common Name: Electrosurgical Device and Accessories
Classification Name: Electrosurgical Cutting and Coagulation
Device and Accessories (21 CFR 878.4400)
Predicate Devices
ArthroCare ArthroWands® K082980
Product Description
The ArthroCare ArthroWands are bipolar, single use, high frequency electrosurgical
devices designed for specific indications in arthroscopic and orthopedic procedures.
12

. x
KX OFS > 3 Ob (2
Oe faye 2 FZ
Intended Uses a
The ArthroCare ArthroWands ate indicated for resection, ablation, and coagulation of
soft tissue and hemostasis of blood vessels in arthroscopic and orthopedic procedures:
 Atthroseopie ahd Orthopedic Procedures, | Joints (ankle, dow,
pe ey hips Knee, shoulder, and |
13

“ ke 083306
—_ f- qo? 4 ©

Continued

SER ee ee ee oh Joints (ankle, elbow,

Arthroscopic and Orthopedic Procedures | uip; knee, shoulder, and

EEUU le ee weep
Substantial Equivalence
This Special 510(k) proposes modifications in the materials specification for the
ArthroCare ArthroWands, which were previously cleared in K082980 (November 5,
2008). The indications for use, technology, principle of operation, and sterilization
parameters of the ArthroCare ArthroWands remain the same as in the predicate cleared
510(k)s.
Summary of Safety and Effectiveness
The modified ArthroCare ArthroWands, as described in this Special 510(k), are
substantially equivalent to the predicate device. The proposed modifications in the
materials is not substantial changes or modifications, and do not significantly affect the
safety or efficacy of the devices.

14

2 J DEPARTMENT OF HEALTH & HUMAN SERVICES Public Heaith Service
4 a
eae Food and Drug Administration
. 9200 Corporate Boul d
DEC 10 208 Rockville MO 20850
Arthrocare Corporation :
% Ms. Valerie Defiesta-Ng
_ Director, Regulatory Affairs
680 Vasqueros Avenue .
Sunnyvale, California 94085-3523 .
Re: K083306
Trade/Device Name: ArthroCare ArthroWands®
Regulation Number: 21 CFR 878.4400 ‘
Regulation Name: Electrosurgical cutting and coagulation device and accessories
Regulatory Class: II
Product Code: GEI ;
; Dated: November 6, 2008 :
Received: November 10, 2008
Dear Ms: Defiesta-Ng: / .
We have reviewed your Section 510(k) premarket notification of intent to market the device
referenced.above and have determinéd the device is substantially equivalent (for the indications
: for use stated in the enclosure) to legally marketed predicate devices marketed in interstate
commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to
devices that have been reclassified in accordance with the provisions of the Federal Food, Drug,
and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).
You may, therefore, market the device, subject to the general controls provisions of the Act. The
general controls provisions of the Act include requirements for annual registration, listing of - :
devices, good manufacturing practice, labeling, and prohibitions against misbranding and
adulteration. ‘ . : : .
: If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it
may be subject‘to such additional controls. Existing major regulations affecting your device can
a be found in the Code of Federal Regulations, Title 21, Parts 800. to 898. In addition, FDA may
publish further announcements concerning your device in the Federal Register.
Please be advised that FDA’s issuance of a substantial equivalence determination doés not mean
__ that FDA has made-a determination that your device complies with other requirements of the Act
or any Federal statutes and-regulations administered by other Federal agencies. You must __. :
. comply with all the Act’s requirements, including, but not limited to: registration and listing, (21
CFR Part 807); labeling (21 ‘CFR Part 801); good. manufacturing practice requirements as set.» :

Page 2 — Ms. Valerie Defiesta-Ng
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic
produet radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.”
This letter will allow you to begin marketing your device as described in your Section 510(k) .

; premarket notification. The FDA finding of substantial equivalence of your device to a legally
marketed predicate device results in a classification for your device and thus, permits your device
to proceed to the market. .
If you desire specific advice for your device on our labeling regulation-(21 CFR Part 801), please
contact the Center for Devices.and Radiological Health’s (CDRH’s) Office of Compliance at
(240) 276-0115. Also, please note the regulation entitled, “Misbranding by reference to
premarket notification” (21CFR Part 807.97). For questions regarding postmarket surveillance,
please contact CDRH’s Office-of Surveillance and Biometric’s (OSB’s) Division of Postmarket
Surveillance at (240).276-3474. For questions regarding the reporting of device adverse events
(Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems ;
at (240) 276-3464, You may obtain other general information on your responsibilities under the
Act from the Division of Small Manufacturers, International and Consumer Assistance
at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address
http://www. fda. gov/cdrh/industry/support/index.htm|. : ,

Sincerely yours,
Mark N. Melkerson
: . Director .
/ Division of General, Restorative /
. . : and Neurological Devices
: , Office of Device Evaluation :
’. Center for Devices and
Radiological Health
______. Enclosure ae cee ce co

Indications for Use Statement
510(k) Number: = K_QO%$ 32306
Device Name ArthroCare ArthroWands®
Indications for Use:
The ArthroCare ArthroWands are indicated for resection, ablation, and coagulation of
soft tissue and hemostasis. of blood vessels in arthroscopic and orthopedic procedures:
ee oN.
eth oscopiG and OvthopedicProtedures JOInsSCankle elbows ie
ee Phi ties Siplele tl
Pe eee WELSH ae
Ablation and Debridement :
+ Acromioplasty ST C*dTSSShoulder
[+ _Chondroplasty «SCA Tits
[+ Notchplasty Rp
: [+ Sear Tissue rains
[+ Subacromial Decompression SSSCS*dYSCCSTSSSolder
AlbJoints
- je Tendon SS*dSC AI ints
| Excision and Resection ,
® Acetabular Labrum . [Bip
*_Articular Labrum ee
¢ Capsular Release 7 :
je Cysts ints
#. Glenoidale Labrum |. Shoulder “|
; «_ Latefal Release [Knee
fe Ligament OT A ints
[eMeniscal Cystectomy sce,
: j XY RN —— —
a, Nirts Goh. Lying
— (Division Sign-Off)) =
Division of General, Restorative,
and Neurological Devices
: : . 10
——-§10(k) Number_ Ko 33306

Continued : .
. ee ee ee | ONSET
, Oe ee in|
“Al dhybstopie ang Ortbopedle procediney ele "end
*__ Plica Removal . | All Toints |
fe SearTisie SS All Joins
| SoftTiswe CSC=*” ~All Joins
* Synovial: Membrane All Joints ‘
«Triangular Bibrocartilage (TRCC) a
Coagulation .
Pe ACLp cL tee
+ Articular Cartilage All Joinis
[+ CatpalLigaments SCS
*  Glenohumeral Capsule : Shoulder
«Medial Retinaculum —_, [Knee +
Shoulder
,
é : /
- Prescription Use xX AND/OR — Over-The-Counter Use ,
(Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C) .
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Lv ,
(Division Sign-Off)
_ Division of Genera}, Restorative,
a ... aid Nevvoiogical Devices
$10) Number_ 0 33306 .
, - 41

